This study evaluated the prognostic value of preoperative pentraxin-3 (PTX3) levels in predicting weight loss, inflammatory resolution (CRP, IL-6), and metabolic improvements (HOMA-IR) following Roux-en-Y gastric bypass in patients with obesity.

This single-center longitudinal study was conducted at Istanbul University Hospital. A total of 23 patients undergoing primary Roux-en-Y gastric bypass were included. PTX3 levels were measured preoperatively, and patients were stratified according to a data-derived cut-off (~21.7 ng/mL). Outcomes assessed at baseline, 3 months, and 6 months included body weight, BMI, excess weight loss (%EWL), fasting insulin, HOMA-IR, CRP, and IL-6. The primary hypothesis was that preoperative PTX3 would predict postoperative CRP normalization and insulin resistance improvement.

Inclusion Criteria:

• Age: 18-65 years
• Body mass index (BMI) ≥40 kg/m², or BMI ≥35 kg/m² with obesity-related comorbidity
• Eligible for primary Roux-en-Y gastric bypass
• Able to provide written informed consent

Exclusion Criteria:

• Previous bariatric surgery
• Severe hepatic, renal, or cardiac failure
• Active infection or inflammatory disease
• Malignancy

Adults with obesity scheduled to undergo primary Roux-en-Y gastric bypass at Istanbul University Hospital.

Sexes Eligible for Study: All Gender-Based: No Accepts Healthy Volunteers: No

The study team does not plan to share individual participant data at this time.